CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
CiMaas announced the grant of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product.
CiMaas moves it's clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
Mr T. Beurskens (Representative Province Limburg on Economy and Knowledge infrastructure) visited CiMaas together with Mrs M. Poulssen (policy advisor Economy and Innovation), Mr M. Cobben (personal assistant) to see current state-of-the-art developments in cell therapy for cancer.